Summary of MEI PHARMA, INC.

Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On January 27, 2013, Professor Bryan R.G. Williams, Ph.D., notified MEI Pharma, Inc. (the "Company") of his decision not to seek re-election to the Board of Directors (the "Board") of the Company upon the expiration of his term at the Company's next annual meeting of stockholders. Professor Williams has been a member of the Board and the Audit Committee of the Board since March 2006, has served as Chairman since November 2006, and has been a member of the Compensation Committee of the Board since 2009. Professor Williams's retirement is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

In light of Professor Williams decision not to seek re-election to the Board, on January 29, 2013, the Board appointed Dr. Christine A. White, who has been a member of the Board since August 2010, to serve as the Board's Lead Director, effective as of the end of Professor Williams's current term and until the Board has made a decision regarding a permanent replacement for Professor Williams as Chairman. The Board has commenced a process to select a new director to fill the vacancy created by Professor Williams's retirement, including through consideration of candidates proposed in accordance with the terms of the Governance Agreements, dated as of December 18, 2012, between the Company and each of Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P.

A press release announcing Professor Williams's retirement and the appointment of Dr. White as Lead Director, dated January 30, 2013, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.